Private services are carrying community pharmacy. Here is what the data shows

Why is community pharmacy turning to private services?

Community pharmacy is turning to private services because the NHS contract no longer covers the cost of operating a pharmacy. Government figures confirmed in a parliamentary written answer that funding for pharmacies in England stood at £3.073 billion in 2025/26, against a real-terms 2015/16 value of £3.864 billion in today's prices, a shortfall of £791 million. The independent economic analysis commissioned by NHS England and carried out by Frontier Economics, published in March 2025, found that pharmacy costs exceeded NHS funding by approximately £2.3 billion in 2024/25.

The consequences are visible in the network itself. According to the House of Commons Library briefing on community pharmacy, updated March 2026, there were 10,526 pharmacies open in England in February 2026 compared with 11,609 in February 2016, a net loss of 1,083 premises. A Community Pharmacy England survey in 2025 found only 6% of owners describing their business as profitable, with 51% saying they were losing money. National Pharmacy Association polling in the same year found 63% of owners believed they could close within twelve months without further support.

The 2025/26 settlement was the largest uplift anywhere in the NHS, worth more than 30% against 2023/24 funding. It has slowed the decline; it has not reversed the arithmetic. A Single Activity Fee of £1.46 per item and £15 per Pharmacy First consultation do not build a margin. What the settlement bought the sector was time, and the owners using that time well are building income streams the Drug Tariff does not touch.

That is not speculation. It is observable in the dispensing data, the Freedom of Information returns and the regulator's own enforcement priorities. Category by category, here is what the numbers show.

How big is the private weight management market for pharmacies?

Private weight management is the largest private prescribing market UK pharmacy has ever seen. IQVIA prescription supply data recorded over 2 million people paying out of pocket for GLP-1 medicines by July 2025, and the Health Foundation put the total number prescribed weight loss medication at an estimated 2.4 million in its February 2026 analysis. Market analysis consistently places the private channel at roughly two thirds of all UK prescription weight loss volume, because NHS eligibility criteria and phased rollout exclude most people who want treatment.

The Health Foundation's dataset of 113,630 private patients shows who is buying: almost eight in ten prescriptions go to women, uptake peaks between ages 30 and 49 and patients in the least deprived areas access treatment at more than twice the rate of those in the most deprived, adjusted for obesity prevalence. Monthly private pricing typically runs from around £140 at starter doses to £300 or more at the highest, particularly since the manufacturer list price increase of September 2025.

Inspectors are now asking to see exactly how that verification happened on individual patient records, not just what the standard operating procedure says should happen. Any pharmacy entering this market should treat that guidance as the design specification for its clinical workflow, not an afterthought.

What is driving demand for private ADHD, TRT and HRT clinics?

Demand for private ADHD and hormone clinics is driven by NHS capacity that has been comprehensively outpaced by referrals. For attention deficit hyperactivity disorder (ADHD), referrals grew by around 400% between 2020 and 2023 while NHS assessment capacity barely moved, and when national management information became visible in 2025 the England-wide open referral count stood at approximately 562,000. Freedom of Information returns from 19 integrated care boards show NHS spending on private ADHD providers rising from £16 million in 2022/23 to £58 million in 2024/25, and NHS England introduced a price cap of roughly £400 per Right to Choose assessment to contain the cost. In December 2025 the government launched a formal review of mental health, ADHD and autism services backed by £688 million. None of that has shortened the queue yet, and private assessment, titration and ongoing supply have become an established pathway, with dispensing of the resulting private prescriptions a service line in its own right.

The hormone picture is similar in shape. NHS Business Services Authority (NHSBSA) statistics published in October 2025 recorded 14.7 million hormone replacement therapy (HRT) items prescribed to an estimated 2.8 million patients in England in 2024/25, an 11% rise in items in one year, and private menopause clinics absorb the demand that NHS primary care cannot schedule. On the men's health side, NHSBSA data reported by The Pharmaceutical Journal shows testosterone items dispensed in the community rose 52% between 2020/21 and 2024/25. Testosterone replacement therapy (TRT) sits in a genuine governance gap: there is no National Institute for Health and Care Excellence guideline for testosterone deficiency in men, and the government's November 2025 men's health strategy does not mention it. That gap is precisely why superintendents involved in TRT dispensing need documented prescriber due diligence, defined blood monitoring intervals and clear referral criteria, because the framework the NHS has not written, your clinical governance has to.

How large is the UK medicinal cannabis market?

The UK medicinal cannabis market is almost entirely private and has more than doubled in a year. NHSBSA Freedom of Information data shows private prescriptions for cannabis-based products for medicinal use rising from around 283,000 in 2023 to 659,000 in 2024, which the Medicinal Cannabis Clinicians Society estimates equates to roughly 80,000 patients once repeat prescribing is accounted for. More than 99% of prescriptions are private; NHS prescribing remains confined to a handful of licensed products and rare cases.

The supply chain rules are strict and specific. Unlicensed cannabis-based medicines can only be initiated by doctors on the General Medical Council Specialist Register, products are Schedule 2 controlled drugs with everything that implies for safe custody, registers and destruction, and the dispensing pharmacy carries full accountability for sourcing, storage and record keeping. The Advisory Council on the Misuse of Drugs has been reviewing the framework since mid 2025 and has noted significant variation in standards across medicinal cannabis dispensing pharmacies. For pharmacy owners, this is a high-growth, high-scrutiny category: the operational bar (controlled drug governance, prescriber verification, batch-level traceability) is the moat as much as the burden.

What about travel vaccines and other private clinical services?

Travel vaccination remains the most accessible private clinical service for a bricks-and-mortar pharmacy because it needs no prescriber partnership and no distance selling infrastructure. Delivery runs on Patient Group Directions (PGDs) purchased from established providers, the consultation is cash-pay at the point of care and the stock (typically hepatitis A, typhoid, rabies, yellow fever where the premises holds a designated centre registration) carries predictable margins. Unlike the categories above, there is no single authoritative national dataset on pharmacy travel clinic revenue, so treat any market-size figure you see quoted with caution. What can be said definitively is operational: a travel clinic is the standard first private service because it trains a team in appointment booking, private record keeping and consultation-room workflow, the same infrastructure every other service on this page depends on.

The same PGD model extends to private flu jabs, meningitis ACWY for Hajj and Umrah travellers, HPV and chickenpox vaccination. Owners who treat these as one bookings-and-records system rather than isolated offerings get the compounding benefit: each service added to an existing clinic infrastructure costs a fraction of the first.

Can you sell POMs and P medicines online legally?

Yes, both prescription-only medicines (POMs) and pharmacy (P) medicines can be sold online legally, but each category has a distinct regulatory architecture and the GPhC's enforcement attention is concentrated here. For POMs, supply must follow a prescription generated through a legitimate prescribing process, and the GPhC's guidance for registered pharmacies providing services at a distance sets out what legitimate means: identity verification, access to or steps to obtain relevant clinical records, safeguards for higher-risk medicines and, since February 2025, independent verification requirements for weight management medicines specifically. The Medicines and Healthcare products Regulatory Agency (MHRA) requires any business selling medicines online to the public to register and display the distance selling logo on every page offering medicines.

Advertising is where online pharmacies most often go wrong. POMs cannot be advertised to the public under the Human Medicines Regulations 2012, full stop. That prohibits naming a POM on a landing page designed to sell it, bidding on branded drug terms and promotional social content, and the MHRA has been actively enforcing against weight loss medicine promotion. The compliant model advertises the service and the condition pathway, never the molecule. P medicines may be advertised, but online supply still requires pharmacist supervision of the sale, meaningful quantity limits and audit trails showing how misuse-prone lines such as codeine-containing products and sleep aids are controlled.

What the data means for pharmacy owners in 2026

The data supports a clear conclusion: private services are no longer a supplement to the NHS contract, they are the margin, and the winners are being decided on operational infrastructure rather than demand. Demand is proven in every category above. What separates the pharmacies capturing it from those watching it is the ability to run bookings, consultations, prescriber workflows, records and dispensing as one system that stands up to inspection.

Two patterns in that table deserve emphasis. First, every high-value category funnels through the same small set of capabilities: verified consultations, complete records, prescriber governance and inspectable audit trails. Second, the regulator moves fastest where growth is fastest. The February 2025 weight management guidance took effect within roughly eighteen months of the private GLP-1 boom beginning, and medicinal cannabis dispensing standards are under active review. Building a service on the assumption that today's light-touch corner stays light touch is how enforcement case studies get written.

The risks the headlines skip

The main risk in private services is not demand collapsing, it is governance failing under growth. GPhC enforcement activity against online pharmacies has concentrated on exactly the services in this article: remote prescribing of weight loss medicines without adequate verification, high-volume supply of misuse-prone medicines and prescribing arrangements where the pharmacy could not evidence who checked what. A superintendent pharmacist is personally accountable for these systems, and "the prescribing was done by a third party" has not protected registrants at fitness-to-practise hearings.

The commercial risks are real too. Private GLP-1 economics shifted overnight when the September 2025 list price increases landed, and patients on the highest doses saw costs jump sharply, which compresses pharmacy margin and increases churn. The ADHD market's pricing is already being shaped by the NHS cap on Right to Choose assessments. Medicinal cannabis remains exposed to the outcome of the ACMD review. None of these are reasons to stay out. They are reasons to build service lines on infrastructure that can flex when a single category wobbles, rather than betting the pharmacy on one molecule's price list.

Key takeaways

FAQs